Want to see ATHE full AI Analyst Report?
ATHE Stock Chart & Stats
$3.55
-$0.16(-4.23%)
At close: 4:00 PM EST
$3.55
-$0.16(-4.23%)
Day’s Range― - ―
52-Week Range$2.66 - $7.00
Previous CloseN/A
Volume131.33K
Average Volume (3M)13.05K
Market Cap
$89.95M
Enterprise Value$78.21M
Total Cash (Recent Filing)$49.15M
Total Debt (Recent Filing)$98.35K
Price to Earnings (P/E)―
Beta1.42
Next Earnings
Mar 04, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.96
Shares Outstanding18,132,430
10 Day Avg. Volume16,981
30 Day Avg. Volume13,055
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.56
Price to Sales (P/S)12.18
P/FCF Ratio-5.79
Enterprise Value/Market Cap0.87
Enterprise Value/Revenue20.40
Enterprise Value/Gross Profit21.07
Enterprise Value/Ebitda-3.94
Forecast
1Y Price Target
$12.67Price Target Upside256.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.47
Revenue Forecast (FY)$4.21M
Bulls Say, Bears Say
Bulls Say
FDA Alignment On Phase 3 ProgramSecuring FDA agreement on trial size, dose, primary endpoint and statistics materially de-risks ATH434's regulatory path. This clarity reduces program execution uncertainty, improves partner and investor confidence, and enables disciplined planning of a registrational program and potential approval timeline.
Validated Imaging Biomarker (QSM)A peer-reviewed, disease-specific biomarker strengthens patient selection, objective endpoints and trial sensitivity for ATH434. Better diagnostics and measurable target engagement lower clinical development risk, can reduce required sample sizes and create a durable competitive advantage in MSA trials.
High Gross Margins With Recent Revenue GrowthSustained gross margins above 90% indicate efficient cost structure relative to revenue and scalable economics if commercialized. Combined with 46% top-line growth, this suggests operational leverage and growing market traction that support long-term gross-profit generation once development succeeds.
Bears Say
Negative Operating And Free Cash FlowsPersistent negative operating and free cash flows create recurring funding requirements and elevate dilution or financing risk. For a clinical-stage biotech, continued cash burn without sustainable cash generation necessitates external capital, which can constrain strategic flexibility and shareholder returns over time.
Negative Return On EquityA negative ROE signals the company is not generating returns from capital invested, reflecting ongoing unprofitability. Over months, continued negative ROE can erode investor confidence and limit access to favorable financing, making it harder to fund pivotal trials or scale commercialization.
Single Lead Asset And Small OrganizationConcentration on one lead program (ATH434) and a very small employee base heighten execution and program risk: a failed pivotal trial or delays would materially impair prospects. Limited internal resources may constrain simultaneous program expansion, commercialization readiness and rapid scale-up.
Alterity Therapeutics News
ATHE FAQ
What was Alterity Therapeutics Ltd’s price range in the past 12 months?
Alterity Therapeutics Ltd lowest stock price was $2.66 and its highest was $7.00 in the past 12 months.
What is Alterity Therapeutics Ltd’s market cap?
Alterity Therapeutics Ltd’s market cap is $89.95M.
When is Alterity Therapeutics Ltd’s upcoming earnings report date?
Alterity Therapeutics Ltd’s upcoming earnings report date is Mar 04, 2027 which is in 226 days.
How were Alterity Therapeutics Ltd’s earnings last quarter?
Alterity Therapeutics Ltd released its earnings results on Feb 25, 2026. The company reported -$0.415 earnings per share for the quarter, missing the consensus estimate of -$0.25 by -$0.165.
Is Alterity Therapeutics Ltd overvalued?
According to Wall Street analysts Alterity Therapeutics Ltd’s price is currently Undervalued.
Does Alterity Therapeutics Ltd pay dividends?
Alterity Therapeutics Ltd does not currently pay dividends.
What is Alterity Therapeutics Ltd’s EPS estimate?
Alterity Therapeutics Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Alterity Therapeutics Ltd have?
Alterity Therapeutics Ltd has 18,132,430 shares outstanding.
What happened to Alterity Therapeutics Ltd’s price movement after its last earnings report?
Alterity Therapeutics Ltd reported an EPS of -$0.415 in its last earnings report, missing expectations of -$0.25. Following the earnings report the stock price went up 2.945%.
Which hedge fund is a major shareholder of Alterity Therapeutics Ltd?
Currently, no hedge funds are holding shares in ATHE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alterity Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
43.18%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
481.25%
Trailing 12-Months
Company Description
Alterity Therapeutics Ltd
Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntington's, and Parkinson's diseases. Its prominent experimental therapy, ATH434, has completed Phase I clinical trials targeting Parkinson's disease. The company is also advancing PBT2, a compound that has successfully undergone Phase IIa clinical testing for Alzheimer's disease. Established in 1997, the entity was formerly known as Prana Biotechnology Limited before rebranding to Alterity Therapeutics Limited in April 2019, and its main operations are based in Melbourne, Australia.
ATHE Stock 12 Month Forecast
Average Price Target
$12.67
▲(256.81% Upside)
Technical Analysis
Ownership Overview
―
Insiders
<0.01% Mutual Funds
0.94% Other Institutional Investors
99.05% Public Companies and
Individual Investors